Melissa Matz1, Michel P Coleman2, Helena Carreira2, Diego Salmerón3, Maria Dolores Chirlaque3, Claudia Allemani2. 1. Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: Melissa.Matz@LSHTM.ac.uk. 2. Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, UK. 3. Department of Epidemiology, Regional Health Council, IMIB, Arrixaca, Murcia, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Department of Health and Social Sciences, Murcia University, Murcia, Spain.
Abstract
OBJECTIVE: Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. METHODS: The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15-99years) diagnosed with ovarian cancer during 1995-2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). RESULTS: Survival from type I epithelial ovarian tumours for women diagnosed during 2005-09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20-45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). CONCLUSIONS: There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.
OBJECTIVE:Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. METHODS: The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15-99years) diagnosed with ovarian cancer during 1995-2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). RESULTS: Survival from type I epithelial ovarian tumours for women diagnosed during 2005-09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20-45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). CONCLUSIONS: There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.
Authors: Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia Journal: Lancet Oncol Date: 2013-12-05 Impact factor: 41.316
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Camille Maringe; Sarah Walters; John Butler; Michel P Coleman; Neville Hacker; Louise Hanna; Berit J Mosgaard; Andy Nordin; Barry Rosen; Gerda Engholm; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Colleen E McGahan; David Meechan; Richard Middleton; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet Journal: Gynecol Oncol Date: 2012-06-27 Impact factor: 5.482
Authors: Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Swantje Piszczan; Dawit Desalegn; Hezkiel Petros; Mengistu Gurmu; Eric Sven Kroeber; Adamu Addissie; Rafael Mikolajczyk; Rahel G Ghebre; Assefa Mathewos; Christoph Thomssen; Ahmedin Jemal; Eva Johanna Kantelhardt Journal: Oncologist Date: 2019-04-25
Authors: Robert L Dood; Nicole D Fleming; Robert L Coleman; Shannon N Westin; Olivia D Lara; Christopher J LaFargue; Jinsong Liu; Anil K Sood Journal: Int J Gynecol Cancer Date: 2018-10 Impact factor: 3.437
Authors: Laura C Hurley; Nancy K Levin; Madhumita Chatterjee; Jasmine Coles; Shlomo Muszkat; Zachary Howarth; Gregory Dyson; Michael A Tainsky Journal: Cancer Biomark Date: 2020 Impact factor: 4.388
Authors: Robert L Dood; Yang Zhao; Shannon D Armbruster; Robert L Coleman; Shelley Tworoger; Anil K Sood; Keith A Baggerly Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777
Authors: Youngjin Han; Boyun Kim; Untack Cho; In Sil Park; Se Ik Kim; Danny N Dhanasekaran; Benjamin K Tsang; Yong Sang Song Journal: Oncogene Date: 2019-08-13 Impact factor: 9.867